Harbour Capital Advisors LLC Acquires New Stake in Allergan PLC. (AGN)
Harbour Capital Advisors LLC acquired a new stake in shares of Allergan PLC. (NYSE:AGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,608 shares of the company’s stock, valued at approximately $384,000.
Several other large investors also recently added to or reduced their stakes in AGN. Crestwood Advisors Group LLC bought a new stake in Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. bought a new stake in Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp increased its stake in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. JNBA Financial Advisors increased its stake in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Finally, Webster Bank N. A. increased its stake in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares during the last quarter. 84.66% of the stock is owned by institutional investors.
Allergan PLC. (NYSE AGN) traded down 3.08% on Friday, reaching $242.65. The company’s stock had a trading volume of 3,014,756 shares. The stock’s 50 day moving average price is $245.21 and its 200 day moving average price is $237.12. The firm has a market cap of $81.50 billion, a PE ratio of 7.56 and a beta of 1.16. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned $3.35 EPS. Equities research analysts expect that Allergan PLC. will post $16.10 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.15%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
Several research firms have recently commented on AGN. UBS AG reissued a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a report on Monday, May 15th. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a report on Monday, June 26th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the company a “buy” rating in a report on Monday, June 12th. BidaskClub raised Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Finally, Mizuho reissued a “buy” rating and issued a $267.00 price objective on shares of Allergan PLC. in a report on Wednesday. Seven analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $274.14.
In other news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.36% of the stock is currently owned by corporate insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.